Close Menu

Amgen

Four related studies out today describe preliminary findings from whole-genome sequences for more than 2,600 Icelanders, offering a glimpse at rarer forms of genetic variation, including loss-of-function mutations affecting both alleles of a gene.

The partners will develop a companion diagnostic for an undisclosed Amgen cancer drug candidate.

A new study of colorectal cancer tissue samples and plasma shows peptide-nucleic-acid-PCR is more sensitive.

NEW YORK (GenomeWeb) — Transgenomic reported today that its third quarter revenues declined 3 percent year over year due to a decrease in sales in both its laboratory services and genetic assays and platform segments.

Wako Pure Chemical Industries has been awarded

NEW YORK (GenomeWeb) – Dutch bioinformatics company Genalice today announced a partnership with Decode Genetics for large-scale testing of the DNA data processing software Genalice Map.

NEW YORK (GenomeWeb) — A group of pharmaceutical companies, research groups, foundations, and the clinical sequencing firm Foundation Medicine have joined to initiate a multi-drug, multi-arm, biomarker-driven clinical trial for patients with squamous cell carcinoma called the Lung Cancer Master P

Originally published June 3.
NEW YORK (GenomeWeb) – Data from two large studies that tested the efficacy of widely used targeted drugs in molecularly defined breast cancer and colorectal cancer populations failed to show superiority of one therapeutic strategy over another.

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Qiagen's Therascreen KRAS RGQ PCR companion test to pick out best responders to Amgen's colorectal cancer drug Vectibix (panitumumab).

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.